Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INI-2004 in Ragweed-induced Allergic Rhinitis
NCT07556393Phase 2Completed
- Sponsor
- Inimmune Corporation
- Start
- Jan 2026
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of INI-2004 in allergic rhinitis (AR), sponsored by Inimmune Corporation. Started Jan 2026; status: completed.
02
Drugs
INI-2004
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07556393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556393.